Anabolic and anticatabolic agents in critical care

Current Opinion in Critical Care

Volumn 22, Issue 4, 2016, Pages 325-331

  Stanojcic, Mile ^a   Finnerty, Celeste C ^b,c   Jeschke, Marc G ^a,d,e,f  

^a Canada   (Canada)

^b UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

^c SHRINERS HOSPITALS FOR CHILDREN   (United States)

^d Division of Plastic Surgery   (United States)

^e SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^f UNIVERSITY OF TORONTO   (Canada)

Author keywords

anabolic; anticatabolic; burns; critical illness; hypermetabolism; insulin; metformin; oxandrolone; propranolol

Indexed keywords

ANABOLIC AGENT; ANTICATABOLIC AGENT; ANTIMETABOLITE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; HUMAN GROWTH HORMONE; INSULIN; KETOCONAZOLE; METFORMIN; OXANDROLONE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PROPRANOLOL; SOMATOMEDIN C; TESTOSTERONE; UNCLASSIFIED DRUG; BETA ADRENERGIC RECEPTOR BLOCKING AGENT;

CATABOLISM; CRITICALLY ILL PATIENT; GLYCEMIC CONTROL; HUMAN; HYPERMETABOLISM; INSULIN TREATMENT; INTENSIVE CARE; MULTICENTER STUDY (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; CRITICAL ILLNESS; PROCEDURES;

ADRENERGIC BETA-ANTAGONISTS; ANABOLIC AGENTS; CRITICAL CARE; CRITICAL ILLNESS; HUMANS; INSULIN; OXANDROLONE; PROPRANOLOL;

EID: 84973392560     PISSN: 10705295     EISSN: 15317072     Source Type: Journal    
DOI: 10.1097/MCC.0000000000000330     Document Type: Review

References (64)

1. Mongardon N, Singer M. The evolutionary role of nutrition and metabolic support in critical illness. Crit Care Clin 2010; 26:443-450.
2. Goldstein DS, Kopin IJ. Evolution of concepts of stress. Stress 2007; 10:109-120.
3. Jeschke MG, Chinkes DL, Finnerty CC, et al. Pathophysiologic response to severe burn injury. Ann Surg 2008; 248:387-401.
4. Williams FN, Herndon DN, Jeschke MG. The hypermetabolic response to burn injury and interventions to modify this response. Clin Plast Surg 2009; 36:583-596.
5. Jeschke MG, Gauglitz GG, Kulp GA, et al. Long-term persistance of the pathophysiologic response to severe burn injury. PLoS One 2011; 6:e21245.
6. Gauglitz GG, Herndon DN, Kulp GA, et al. Abnormal insulin sensitivity persists up to three years in pediatric patients postburn. J Clin Endocrinol Metab 2009; 94:1656-1664.
7. Jeschke MG, Barrow RE, Herndon DN. Extended hypermetabolic response of the liver in severely burned pediatric patients. Arch Surg 2004; 139:641-647.
8. Herndon DN, Tompkins RG. Support of the metabolic response to burn injury. Lancet 2004; 363:1895-1902.
9. Randle PJ, Garland PB, Hales CN, Newsholme EA. The glucose fatty-acid cycle. Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet 1963; 1:785-789.
10. Boden G, Chen X, Ruiz J, et al. Insulin receptor down-regulation and impaired antilipolytic action of insulin in diabetic patients after pancreas/kidney transplantation. J Clin Endocrinol Metab 1994; 78:657-663.
11. Shah P, Vella A, Basu A, et al. Effects of free fatty acids and glycerol on splanchnic glucose metabolism and insulin extraction in nondiabetic humans. Diabetes 2002; 51:301-310.
12. Dresner A, Laurent D, Marcucci M, et al. Effects of free fatty acids on glucose transport and IRS-1-associated phosphatidylinositol 3-kinase activity. J Clin Invest 1999; 103:253-259.
13. Pankow JS, Duncan BB, Schmidt MI, et al. Fasting plasma free fatty acids and risk of type 2 diabetes: the atherosclerosis risk in communities study. Diabetes Care 2004; 27:77-82.
14. Hart DW, Wolf SE, Mlcak R, et al. Persistence of muscle catabolism after severe burn. Surgery 2000; 128:312-319.
15. Hart DW, Wolf SE, Chinkes DL, et al. Determinants of skeletal muscle catabolism after severe burn. Ann Surg 2000; 232:455-465.
16. Lang CH, Dobrescu C, Bagby GJ. Tumor necrosis factor impairs insulin action on peripheral glucose disposal and hepatic glucose output. Endocrinology 1992; 130:43-52.
17. Hart DW, Wolf SE, Zhang XJ, et al. Efficacy of a high-carbohydrate diet in catabolic illness. Critical care medicine 2001; 29:1318-1324.
18. Mlcak RP, Suman OE, Murphy K, Herndon DN. Effects of growth hormone on anthropometric measurements and cardiac function in children with thermal injury. Burns 2005; 31:60-66.
19. Wu X, Herndon DN, Wolf SE. Growth hormone down-regulation of interleukin-1beta and interleukin-6 induced acute phase protein gene expression is associated with increased gene expression of suppressor of cytokine signal-3. Shock 2003; 19:314-320.
20. Aili Low JF, Barrow RE, Mittendorfer B, et al. The effect of short-term growth hormone treatment on growth and energy expenditure in burned children. Burns 2001; 27:447-452.
21. Williams FN, Jeschke MG, Chinkes DL, et al. Modulation of the hypermetabolic response to trauma: temperature, nutrition, and drugs. J Am Coll Surg 2009; 208:489-502.
22. Branski LK, Herndon DN, Barrow RE, et al. Randomized controlled trial to determine the efficacy of long-term growth hormone treatment in severely burned children. Ann Surg 2009; 250:514-523.
23. Takala J, Ruokonen E, Webster NR, et al. Increased mortality associated with growth hormone treatment in critically ill adults. New Engl J Med 1999; 341:785-792.
24. Heszele MF, Price SR. Insulin-like growth factor I: the yin and yang of muscle atrophy. Endocrinology 2004; 145:4803-4805.
25. Jeschke MG, Barrow RE, Herndon DN. Recombinant human growth hormone treatment in pediatric burn patients and its role during the hepatic acute phase response. Crit Care Med 2000; 28:1578-1584.
26. Spies M, Wolf SE, Barrow RE, et al. Modulation of types I and II acute phase reactants with insulin-like growth factor-1/binding protein-3 complex in severely burned children. Crit Care Med 2002; 30:83-88.
27. Langouche L, van den Berghe G. Glucose metabolism and insulin therapy. Crit Care Clin 2006; 22:119-129.
28. Dimitriadis G, Mitrou P, Lambadiari V, et al. Insulin effects in muscle and adipose tissue. Diabetes Res Clin Pract 2011; 93 (Suppl 1):S52-S59.
29. Jeschke MG, Barrow RE, Mlcak RP, Herndon DN. Endogenous anabolic hormones and hypermetabolism: effect of trauma and gender differences. Ann Surg 2005; 241:759-767.
30. Jeschke MG, Klein D, Herndon DN. Insulin treatment improves the systemic inflammatory reaction to severe trauma. Ann Surg 2004; 239:553-560.
31. Thomas SJ, Morimoto K, Herndon DN, et al. The effect of prolonged euglycemic hyperinsulinemia on lean body mass after severe burn. Surgery 2002; 132:341-347.
32. Brunkhorst FM, Engel C, Bloos F, et al. Intensive insulin therapy and pentastarch resuscitation in severe sepsis. N Engl J Med 2008; 358:125-139.
33. Langouche L, Vander Perre S, Wouters PJ, et al. Effect of intensive insulin therapy on insulin sensitivity in the critically ill. J Clin Endocrinol Metab 2007; 92:3890-3897.
34. Finney SJ, Zekveld C, Elia A, Evans TW. Glucose control and mortality in critically ill patients. JAMA 2003; 290:2041-2047.
35. Dellinger RP, Levy MM, Carlet JM, et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med 2008; 36:296-327.
36. Jeschke MG, Kraft R, Emdad F, et al. Glucose control in severely thermally injured pediatric patients: what glucose range should be the target? Ann Surg 2010; 252:521-527.
37. Suman OE, Thomas SJ, Wilkins JP, et al. Effect of exogenous growth hormone and exercise on lean mass and muscle function in children with burns. J Appl Physiol (1985) 2003; 94:2273-2281.
38. Ferrando AA, Sheffield-Moore M, Wolf SE, et al. Testosterone administration in severe burns ameliorates muscle catabolism. Crit Care Med 2001; 29:1936-1942.
39. Loose DS, Kan PB, Hirst MA, et al. Ketoconazole blocks adrenal steroidogenesis by inhibiting cytochrome P450-dependent enzymes. J Clin Invest 1983; 71:1495-1499.
40. Pont A, Williams PL, Loose DS, et al. Ketoconazole blocks adrenal steroid synthesis. Ann Intern Med 1982; 97:370-372.
41. Jeschke MG, Williams FN, Finnerty CC, et al. The effect of ketoconazole on post-burn inflammation, hypermetabolism and clinical outcomes. PLosS One 2012; 7:e35465.
42. Hart DW, Wolf SE, Ramzy PI, et al. Anabolic effects of oxandrolone after severe burn. Ann Surg 2001; 233:556-564.
43. Demling RH, Orgill DP. The anticatabolic and wound healing effects of the testosterone analog oxandrolone after severe burn injury. J Crit Care 2000; 15:12-17.
44. Wolf SE, Edelman LS, Kemalyan N, et al. Effects of oxandrolone on outcome measures in the severely burned: a multicenter prospective randomized double-blind trial. J Burn Care Res 2006; 27:131-141.
45. Jeschke MG, Finnerty CC, Suman OE, et al. The effect of oxandrolone on the endocrinologic, inflammatory, and hypermetabolic responses during the acute phase postburn. Ann Surg 2007; 246:351-362.
46. Demling RH, DeSanti L. The rate of restoration of body weight after burn injury, using the anabolic agent oxandrolone, is not age dependent. Burns 2001; 27:46-51.
47. Murphy KD, Thomas S, Mlcak RP, et al. Effects of long-term oxandrolone administration in severely burned children. Surgery 2004; 136:219-224.
48. Porro LJ, Herndon DN, Rodriguez NA, et al. Five-year outcomes after oxandrolone administration in severely burned children: a randomized clinical trial of safety and efficacy. J Am Coll Surg 2012; 214:489-502.
49. Sousse LE, Herndon DN, Mlcak RP, et al. Long-term administration of oxandrolone improves lung function in pediatric burned patients. J Burn Care Res 2016. [Epub ahead of print]
50. Reeves PT, Herndon DN, Tanksley JD, et al. Five-year outcomes after longterm oxandrolone administration in severely burned children: a randomized clinical trial. Shock 2016; 45:367-374.
51. Herndon DN, Hart DW, Wolf SE, et al. Reversal of catabolism by betablockade after severe burns. N Engl J Med 2001; 345:1223-1229.
52. Williams FN, Herndon DN, Kulp GA, Jeschke MG. Propranolol decreases cardiac work in a dose-dependent manner in severely burned children. Surgery 2010; 149:231-239.
53. Hart DW, Wolf SE, Chinkes DL, et al. Beta-blockade and growth hormone after burn. Ann Surg 2002; 236:450-456.
54. Jeschke MG, Finnerty CC, Kulp GA, et al. Combination of recombinant human growth hormone and propranolol decreases hypermetabolism and inflammation in severely burned children. Pediatr Crit Care Med 2008; 9:209-216.
55. Barret JP, Jeschke MG, Herndon DN. Fatty infiltration of the liver in severely burned pediatric patients: autopsy findings and clinical implications. J Trauma 2001; 51:736-739.
56. Pereira CT, Jeschke MG, Herndon DN. Beta-blockade in burns. Novartis Found Symp 2007; 280:238-248.
57. Herndon DN, Rodriguez NA, Diaz EC, et al. Long-term propranolol use in severely burned pediatric patients: a randomized controlled study. Ann Surg 2012; 256:402-411.
58. Gore DC, Wolf SE, Herndon DN, Wolfe RR. Metformin blunts stress-induced hyperglycemia after thermal injury. J Trauma 2003; 54:555-561.
59. Gore DC, Wolf SE, Sanford A, et al. Influence of metformin on glucose intolerance and muscle catabolism following severe burn injury. Ann Surg 2005; 241:334-342.
60. Jeschke MG, Abdullahi A, Burnett M, et al. Glucose control in severely burned patients using metformin-an interim safety and efficacy analysis of a Phase II randomized controlled trial. Ann Surg 2016 (in press).
61. Bailey CJ, Turner RC. Metformin. N Engl J Med 1996; 334:574-579.
62. Cree MG, Zwetsloot JJ, Herndon DN, et al. Insulin sensitivity and mitochondrial function are improved in children with burn injury during a randomized controlled trial of fenofibrate. Ann Surg 2007; 245:214-221.
63. Deane AM, Chapman MJ, Fraser RJ, et al. The effect of exogenous glucagonlike peptide-1 on the glycaemic response to small intestinal nutrient in the critically ill: a randomised double-blind placebo-controlled cross over study. Crit Care 2009; 13:R67.
64. Minnich A, Tian N, Byan L, Bilder G. A potent PPARalpha agonist stimulates mitochondrial fatty acid beta-oxidation in liver and skeletal muscle. Am J Physiol Endocrinol Metab 2001; 280:E270-E279.